On Friday, Lyra Therapeutics Inc (NASDAQ: LYRA) opened higher 5.88% from the last session, before settling in for the closing price of $0.17. Price fluctuations for LYRA have ranged from $0.16 to $6.79 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 58.51%. Company’s average yearly earnings per share was noted -6.83% at the time writing. With a float of $54.79 million, this company’s outstanding shares have now reached $65.46 million.
Let’s determine the extent of company efficiency that accounts for 88 employees. In terms of profitability, gross margin is -816.72%, operating margin of -6894.43%, and the pretax margin is -6632.36%.
Lyra Therapeutics Inc (LYRA) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Lyra Therapeutics Inc is 16.29%, while institutional ownership is 46.47%.
Lyra Therapeutics Inc (LYRA) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -6.83% per share during the next fiscal year.
Lyra Therapeutics Inc (NASDAQ: LYRA) Trading Performance Indicators
Check out the current performance indicators for Lyra Therapeutics Inc (LYRA). In the past quarter, the stock posted a quick ratio of 3.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.48.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.53, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.64 in one year’s time.
Technical Analysis of Lyra Therapeutics Inc (LYRA)
Looking closely at Lyra Therapeutics Inc (NASDAQ: LYRA), its last 5-days average volume was 1.79 million, which is a jump from its year-to-date volume of 1.7 million. As of the previous 9 days, the stock’s Stochastic %D was 13.57%. Additionally, its Average True Range was 0.02.
During the past 100 days, Lyra Therapeutics Inc’s (LYRA) raw stochastic average was set at 9.64%, which indicates a significant decrease from 20.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.10% in the past 14 days, which was lower than the 93.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.2215, while its 200-day Moving Average is $1.3232. However, in the short run, Lyra Therapeutics Inc’s stock first resistance to watch stands at $0.1882. Second resistance stands at $0.1965. The third major resistance level sits at $0.2078. If the price goes on to break the first support level at $0.1686, it is likely to go to the next support level at $0.1573. Now, if the price goes above the second support level, the third support stands at $0.1490.
Lyra Therapeutics Inc (NASDAQ: LYRA) Key Stats
There are currently 65,458K shares outstanding in the company with a market cap of 12.47 million. Presently, the company’s annual sales total 1,560 K according to its annual income of -62,680 K. Last quarter, the company’s sales amounted to 200 K and its income totaled -11,870 K.
